drugset / Trial / NCT04026165
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
RandomizedSequentialDouble-blindTreatment
Summary
The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
Timeline
- Start
- 2019-07-24
- Primary completion
- 2021-09-03
- Completion
- 2021-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selonsertib | Small molecule | 18 mg | Oral |